132 related articles for article (PubMed ID: 37247931)
21. Combination effects of amino acid transporter LAT1 inhibitor nanvuranlat and cytotoxic anticancer drug gemcitabine on pancreatic and biliary tract cancer cells.
Nishikubo K; Ohgaki R; Liu X; Okanishi H; Xu M; Endou H; Kanai Y
Cancer Cell Int; 2023 Jun; 23(1):116. PubMed ID: 37322479
[TBL] [Abstract][Full Text] [Related]
22. Hemocompatible LAT1-inhibitor can induce apoptosis in cancer cells without affecting brain amino acid homeostasis.
Markowicz-Piasecka M; Huttunen J; Montaser A; Huttunen KM
Apoptosis; 2020 Jun; 25(5-6):426-440. PubMed ID: 32405891
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of cancer-type amino acid transporter LAT1 suppresses B16-F10 melanoma metastasis in mouse models.
Shi Z; Kaneda-Nakashima K; Ohgaki R; Xu M; Okanishi H; Endou H; Nagamori S; Kanai Y
Sci Rep; 2023 Aug; 13(1):13943. PubMed ID: 37626086
[TBL] [Abstract][Full Text] [Related]
24. Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma.
Caumanns JJ; Berns K; Wisman GBA; Fehrmann RSN; Tomar T; Klip H; Meersma GJ; Hijmans EM; Gennissen AMC; Duiker EW; Weening D; Itamochi H; Kluin RJC; Reyners AKL; Birrer MJ; Salvesen HB; Vergote I; van Nieuwenhuysen E; Brenton J; Braicu EI; Kupryjanczyk J; Spiewankiewicz B; Mittempergher L; Bernards R; van der Zee AGJ; de Jong S
Clin Cancer Res; 2018 Aug; 24(16):3928-3940. PubMed ID: 29685880
[No Abstract] [Full Text] [Related]
25. Targeting STAT3 by HO3867 induces apoptosis in ovarian clear cell carcinoma.
Bixel K; Saini U; Kumar Bid H; Fowler J; Riley M; Wanner R; Deepa Priya Dorayappan K; Rajendran S; Konishi I; Matsumura N; Cohn DE; Selvendiran K
Int J Cancer; 2017 Nov; 141(9):1856-1866. PubMed ID: 28646535
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of PI3K/AKT/mTOR and MAPK signaling pathways decreases progranulin expression in ovarian clear cell carcinoma (OCCC) cell line: a potential biomarker for therapy response to signaling pathway inhibitors.
Perez-Juarez CE; Arechavaleta-Velasco F; Zeferino-Toquero M; Alvarez-Arellano L; Estrada-Moscoso I; Diaz-Cueto L
Med Oncol; 2019 Nov; 37(1):4. PubMed ID: 31713081
[TBL] [Abstract][Full Text] [Related]
27. Targeting an autocrine IL-6-SPINK1 signaling axis to suppress metastatic spread in ovarian clear cell carcinoma.
Mehner C; Miller E; Hockla A; Coban M; Weroha SJ; Radisky DC; Radisky ES
Oncogene; 2020 Oct; 39(42):6606-6618. PubMed ID: 32929152
[TBL] [Abstract][Full Text] [Related]
28. The LAT1 inhibitor JPH203 suppresses the growth of castration-resistant prostate cancer through a CD24-mediated mechanism.
Saito S; Ando K; Sakamoto S; Xu M; Yamada Y; Rii J; Kanaoka S; Wei J; Zhao X; Pae S; Kanesaka M; Goto Y; Sazuka T; Imamura Y; Reien Y; Hamaguchi-Suzuki N; Saito S; Hirayama Y; Hashimoto H; Kanai Y; Ichikawa T; Anzai N
Cancer Sci; 2024 Apr; ():. PubMed ID: 38655663
[TBL] [Abstract][Full Text] [Related]
29. Characterization of Mutational Status, Spheroid Formation, and Drug Response of a New Genomically-Stable Human Ovarian Clear Cell Carcinoma Cell Line, 105C.
Kolendowski B; Valdes YR; Hirte H; Itamochi H; Lee W; Carey M; Shepherd TG; DiMattia GE
Cells; 2020 Nov; 9(11):. PubMed ID: 33153119
[TBL] [Abstract][Full Text] [Related]
30. Upregulation of ATF4 mediates the cellular adaptation to pharmacologic inhibition of amino acid transporter LAT1 in pancreatic ductal adenocarcinoma cells.
Ma Y; Okuda S; Okanishi H; Xu M; Jin C; Endou H; Ohgaki R; Kanai Y
J Pharmacol Sci; 2024 May; 155(1):14-20. PubMed ID: 38553134
[TBL] [Abstract][Full Text] [Related]
31. An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience.
Oliver KE; Brady WE; Birrer M; Gershenson DM; Fleming G; Copeland LJ; Tewari K; Argenta PA; Mannel RS; Secord AA; Stephan JM; Mutch DG; Stehman FB; Muggia FM; Rose PG; Armstrong DK; Bookman MA; Burger RA; Farley JH
Gynecol Oncol; 2017 Nov; 147(2):243-249. PubMed ID: 28807367
[TBL] [Abstract][Full Text] [Related]
32. Enhanced tumor growth elicited by L-type amino acid transporter 1 in human malignant glioma cells.
Kobayashi K; Ohnishi A; Promsuk J; Shimizu S; Kanai Y; Shiokawa Y; Nagane M
Neurosurgery; 2008 Feb; 62(2):493-503; discussion 503-4. PubMed ID: 18382329
[TBL] [Abstract][Full Text] [Related]
33. Targeted Suppression and Knockout of ASCT2 or LAT1 in Epithelial and Mesenchymal Human Liver Cancer Cells Fail to Inhibit Growth.
Bothwell PJ; Kron CD; Wittke EF; Czerniak BN; Bode BP
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30029480
[TBL] [Abstract][Full Text] [Related]
34. Characterization of the expression of LAT1 as a prognostic indicator and a therapeutic target in renal cell carcinoma.
Higuchi K; Sakamoto S; Ando K; Maimaiti M; Takeshita N; Okunushi K; Reien Y; Imamura Y; Sazuka T; Nakamura K; Matsushima J; Furihata T; Ikehara Y; Ichikawa T; Anzai N
Sci Rep; 2019 Nov; 9(1):16776. PubMed ID: 31748583
[TBL] [Abstract][Full Text] [Related]
35. Amino acid transporter LAT1 in tumor-associated vascular endothelium promotes angiogenesis by regulating cell proliferation and VEGF-A-dependent mTORC1 activation.
Quan L; Ohgaki R; Hara S; Okuda S; Wei L; Okanishi H; Nagamori S; Endou H; Kanai Y
J Exp Clin Cancer Res; 2020 Nov; 39(1):266. PubMed ID: 33256804
[TBL] [Abstract][Full Text] [Related]
36. Up-Regulation of LAT1 during Antiandrogen Therapy Contributes to Progression in Prostate Cancer Cells.
Xu M; Sakamoto S; Matsushima J; Kimura T; Ueda T; Mizokami A; Kanai Y; Ichikawa T
J Urol; 2016 May; 195(5):1588-1597. PubMed ID: 26682754
[TBL] [Abstract][Full Text] [Related]
37. Relationship between LAT1 expression and response to platinum-based chemotherapy in non-small cell lung cancer patients with postoperative recurrence.
Kaira K; Takahashi T; Murakami H; Shukuya T; Kenmotsu H; Naito T; Oriuchi N; Kanai Y; Endo M; Kondo H; Nakajima T; Yamamoto N
Anticancer Res; 2011 Nov; 31(11):3775-82. PubMed ID: 22110199
[TBL] [Abstract][Full Text] [Related]
38. Proteomics and phosphoproteomics reveal key regulators associated with cytostatic effect of amino acid transporter LAT1 inhibitor.
Okanishi H; Ohgaki R; Okuda S; Endou H; Kanai Y
Cancer Sci; 2021 Feb; 112(2):871-883. PubMed ID: 33264461
[TBL] [Abstract][Full Text] [Related]
39. Targeting Amino Acid Metabolic Reprogramming via L-Type Amino Acid Transporter 1 (LAT1) for Endocrine-Resistant Breast Cancer.
Shindo H; Harada-Shoji N; Ebata A; Sato M; Soga T; Miyashita M; Tada H; Kawai M; Kosaka S; Onuki K; Usami S; Furumoto S; Hayashi S; Abe T; Suzuki T; Ishida T; Sasano H
Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503187
[TBL] [Abstract][Full Text] [Related]
40. Hepatocyte nuclear factor-1β (HNF-1β) promotes glucose uptake and glycolytic activity in ovarian clear cell carcinoma.
Okamoto T; Mandai M; Matsumura N; Yamaguchi K; Kondoh H; Amano Y; Baba T; Hamanishi J; Abiko K; Kosaka K; Murphy SK; Mori S; Konishi I
Mol Carcinog; 2015 Jan; 54(1):35-49. PubMed ID: 24105991
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
